However, plasmin-mediated hyperfibrinolysis may also be corrected by all-trans retinoic acid (ATRA) or ATRA plus arsenic trioxide therapy in patients with APL [70] by downregulating ANXA2 expression [71]. The gene discussed is PLG; the disease is acute promyelocytic leukemia.